Busulfan (BU) has a narrow therapeutic window and the average concentration of BU at steady state (Css) is critical for successful engraftment in children receiving BU as part of the preparative regimen for allogeneic transplants. Sixteen patients with sickle cell disease (SCD) underwent allogeneic bone marrow transplant (BMT) from HLA-identical siblings. The preparative regimen consisted of intravenous BU 0.8-1 mg/kg/dose for 16 doses, cytoxan (CY) of 50 mg/kg daily for four doses and equine anti-thymocyte globulin (ATG) 30 mg/kg daily for three doses. BU levels were adjusted to provide a total exposure Css of 600-700 ng/mL. The median age at the time of transplant was 6.2 years (range 1.2-19.3). Fourteen (87%) patients required adjustment of the BU dose to achieve a median Css of 652 ng/mL (range 607-700). All patients achieved neutrophil and platelet engraftment without significant toxicity. Median donor engraftment at the last follow-up was 100% (range 80-100). None of the patients experienced sickle cell-related complications post transplant. With a median follow-up of 3 years (range 1.3-9), the event-free survival (EFS) and overall survival (OS) are both 100%. We conclude that targeting of BU Css between 600 and 700 ng/mL in this regimen can result in excellent and sustained engraftment in young patients with SCD.
INTRODUCTION
Sickle cell disease (SCD) is one of the common hemoglobinopathies worldwide and is the most common genetic disease in the US. It is a chronic illness with significant morbidity and mortality. Complications include vaso-occlusive pain crises, increased infection, acute chest syndrome and stroke, as well as multiple organ damage, resulting in reduced life expectancy. Red blood cell (RBC) transfusions and hydroxyurea are effective treatments to reduce the complications of SCD, but the only curative therapy is allogeneic hematopoietic stem cell transplant (HSCT). The suppression of endogenous sickle cell production by regular transfusion of RBCs is highly effective, but inevitably causes iron overload and can be limited by alloimmunization. Despite blood transfusions after an overt stroke, 17.5% of the patients suffer recurrence and 30% of the patients experience new silent cerebral infarcts. 1 Hydroxyurea is remarkable in ameliorating sickle cell symptoms and increasing survival, but it is a long-term medication and does not prevent all complications of SCD. The only curative therapy is replacing the sickle erythrocyte progenitors with normal erythrocyte progenitors through allogeneic HSCT. Concerns of toxicities related to conditioning therapy and paucity of matched siblings have limited the use of transplantation in SCD. The experience of allogeneic HSCT for SCD in the pediatric population has been reported in several large studies since the 1990s. [2] [3] [4] The majority have been HLA-identical sibling transplants using the standard BU, CY and ATG preparative regimens. [3] [4] [5] [6] OS is 95-97%, but EFS is lower at 85%. The major complications of HSCT include transplant-related toxicities and graft rejection. Recent emphasis in HSCT for SCD has been on optimizing preparative regimens to achieve engraftment and cure with minimal toxicity.
BU in combination with CY are the main agents used for myeloablative transplants in SCD. Higher BU exposure has been associated with hepatic veno-occlusive disease, seizures, interstitial pneumonitis and mortality, whereas lower BU dosing increases graft rejection. [7] [8] [9] In young children, the same normalized BU dose achieves a substantially lower average concentration at steady state (Css) or area under the curve (AUC) compared with adults. 7, 9 In a prospective oral BU pharmacokinetic (PK) study, BU Css below 600 ng/mL significantly correlated with non-engraftment and mixed chimerism. 7 This finding was corroborated by a retrospective analysis of 53 children receiving oral BU in which BU Css 4600 ng/ mL predicted a low probability of rejection. 9 Although BU has been commonly administered intravenously in recent years, the observations of the importance of the therapeutic window of BU exposure from these studies remain valid.
Concerns of transplant complications have limited the use of HSCT in SCD. To increase the acceptability of match-related HSCT as a therapeutic option, we aimed to minimize transplant-related toxicity and achieve high levels of donor engraftment by the strict targeting of BU Css between 600-700 ng/mL in a standard i.v. BU and CY preparative regimen for HLA-identical transplants in SCD.
MATERIALS AND METHODS
Between May 2004 and May 2012, 16 patients with SCD underwent myeloablative BMT from HLA-identical sibling donors on a standard institutional protocol. All patients underwent thorough organ function evaluation before transplant and met the protocol stated organ functions. The patients were required to have a cardiac-ejection fraction of X50% and pulmonary function showing lung diffusing capacity (DLCO) of 460% predicted. For younger patients unable to have pulmonary function tests, a normal chest X-ray and oxygen saturation of 490% on room air were required. Renal function was evaluated and measured glomerular filtration rate of 460 mL/min was part of the inclusion criteria. All patients were admitted to a dedicated SCT unit with hepafiltration.
The preparative regimens consisted of i.v. BU at a starting dose of 0.8 mg/ kg/dose for patients 44 years of age and 1 mg/kg/dose i.v. for patients 4 years of age or younger, administered every 6 h for a total of 16 doses over 4 days (days À 9 to À 6), CY at 50 mg/kg/dose once daily for 4 days (days À 5 to À 2) and equine antithymocyte globulin at 30 mg/kg/dose daily for 3 days (days À 3 to À 1). Patient-specific BU PK analysis was performed with the first dose. Dose adjustments were made for doses 7-16 as needed to target an average Css exposure range between 600 and 700 ng/mL (AUC 877 to 1023 mmol*min) over the 4 days of BU administration. All patients received a BM graft infused through a central venous catheter. Graft versus host disease (GVHD) prophylaxis consisted of cyclosporine starting 2 days before the transplant, MTX 15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3, þ 6 and þ 11. The cyclosporine dose was adjusted to achieve a level of 150-250 ng/mL. Cyclosporine was continued until 6 months post transplant and, in the absence of GVHD, patients were gradually weaned off by 9 months post transplant. All transplants were performed in the summer season to avoid complications related to respiratory viral infections.
PK sampling and analysis
Blood samples were collected in sodium heparin tubes after BU dose 1. These samples were drawn at the end of the 2-h infusion and at 135, 150, 180, 240, 300 and 360 min after the beginning of the infusion. Samples were stored on wet ice or refrigerated, plasma was separated and frozen. Frozen plasma was shipped on dry ice to an outside laboratory for analysis (Seattle Cancer Care Alliance Pharmacokinetics Laboratory, Seattle, WA). Plasma BU concentrations were analyzed by gas chromatography with mass selective detection, as previously described, 10 with intraday and interday coefficient of variations less than 5% and 8%, respectively.
Individual patients' concentration-time data were fit using the singlecompartment, first-order elimination model in WinNonlin version 4.0 or 5.2 (Pharsight Corporation, Mountain View, CA, USA). Clearance and Css were calculated based on the following equations: clearance ¼ dose divided by AUC and Css ¼ AUC divided by dosing interval. Css was calculated as AUC 0 to N multiplied by BU MW (246.3 g/mol) divided by the dosing interval (6 h). After calculation of the patient's clearance, the target dose for subsequent doses was calculated linearly to achieve the target Css. Dose adjustments were made beginning with dose 7 as PK results were not available until day 2 of BU.
Supportive care
Before the start of the preparative regimen, patients received a RBC transfusion for a serum hemoglobin (Hb) goal of 10 g/dL. All patients received seizure prophylaxis with levetiracetam 24 h before the start of BU and continued until the patients were off cyclosporine to minimize the risk of seizures. All patients received amlodipine for blood pressure control starting 2 days pre-transplant until they were off cyclosporine, and the dose was aggressively adjusted to maintain normal blood pressure for age. All patients received RBC transfusions to maintain a Hb level of 10 g/dL and platelet transfusions to maintain a platelet count of X30 000/mL post transplant. All patients received broad-spectrum third generation cephalosporin prophylaxis during the neutropenic phase post transplant. Viral prophylaxis with acyclovir was given from the time of transplant until the discontinuation of immune suppression, and fungal prophylaxis with fluconazole was given from the day of transplant until 3 months post transplant.
Definitions and chimerism analysis
Neutrophil engraftment is defined as the first day of 3 consecutive days of neutrophil count of X500/mL. Sinusoidal obstructive syndrome (SOS), formerly known as the veno-occlusive disease of the liver, and GVHD were diagnosed and graded using previously published criteria. 8, 11 Chimerism analysis was performed by comparing high-MW genomic DNA extracted from whole-blood specimens received from the donor and recipient before transplantation, and whole-blood on samples following transplantation. DNA (5-20 ng) from each specimen was analyzed using fluorescent PCR amplification for nine highly polymorphic independently segregating STR loci and a gender-specific locus (Applied Biosystems, Foster City, CA, USA). Chimerism analysis was performed 30 days post transplant and every 3 months thereafter until 2 years post transplant, then yearly. Hb electrophoresis was performed starting 3 months post transplant and every 3 months for 2 years, then annually.
RESULTS
A total of 16 patients received allogeneic BMT. The median age was 6.2 years (range 1.2-19.3) with 11 of the patients 6 years or younger and 9 of the 16 were males. The indications for transplant included prior stroke (n ¼ 1), abnormal transcranial doppler (TCD) (n ¼ 1), veno-occlusive crisis or acute chest syndrome in the remaining patients. Six patients had few (1-2) prior veno-occlusive crisis, but the parents were interested in pursuing curative transplant. Two (13%) of the patients had been on chronic transfusions before transplant, whereas four (25%) have not received any transfusions before referral for transplant. All patients had pre-transplant ferritin within the normal range; except for one chronically transfused patient who had a pre-transplant ferritin value of 1000 ng/mL. Detailed patient characteristics are shown in Table 1 . The median overall average BU Css was 652 ng/mL (range 607-700). Dose adjustment was done on 14 (88%) of the patients. The median total dose of BU delivered was 14.7 mg/kg (range 8.95-19.0). Additional BU PK data are presented in Table 2 . The dose of BU was increased in nine (56%) patients, decreased in five (31%) patients and not changed in two (13%) patients based on the PK obtained after the first dose. Three patients (19%) developed grade II stomatitis and required total parental nutrition for 7-14 days post transplant. None of the patients developed SOS and there was no immediate pulmonary, cardiac or renal Targeted BU for HSCT for sickle cell disease S Maheshwari et al dysfunction in the immediate post-transplant period. All patients achieved neutrophil and platelet engraftment at a median of 18 days (14-22) and 22 days (15-26) post transplant, respectively. Grade II acute GVHD developed in two (13%) patients, and none of the patients developed grade III-IV acute or chronic GVHD. Two patients developed posterior reversible encephalopathy syndrome related to cyclosporine use that resolved after switching to tacrolimus. All patients achieved donor engraftment at the first evaluation 30 days post transplant. At a median follow-up of 3 years (range 1.3-9), the median donor engraftment was 100% (range 80-100). All patients are off immune suppression with Hb evaluation identical to their sibling donor ( Table 3 ). The OS and sickle cell disease free survival at 3 years is 100%. The long-term follow-up included cardiac, pulmonary and endocrine evaluation. On cardiac evaluation, all patients continue to have normal cardiac function evaluated annually by a cardiac echocardiogram. Pulmonary function testing was performed on 12 patients who were older than 6 years at the last follow-up. Eleven patients showed normal pulmonary function at the latest annual follow-up, whereas one patient (UPN 1) who had a moderate to severe obstructive defect showed an improvement in pulmonary function at the follow-up. Thyroid and growth hormone levels were normal in 14 patients evaluated. One patient (UPN 14) had pre-existing growth hormone deficiency and was receiving growth hormone injections before transplant. Gonadal function was evaluated in one female and four male patients who were older than 12 at the time of the last follow-up. One male and one female experienced gonadal failure requiring hormone replacement therapy.
DISCUSSION
We report on the outcome of children with SCD receiving allogeneic BMT with strict dosing of BU to a Css between 600-700 ng/mL. All our patients have sustained donor engraftment with minimal regimen-related toxicity. BU concentrations have correlated with the risk of rejection in pediatric patients undergoing BMT. The PKs of high-dose BU are age-dependent, with children having lower plasma levels when compared with adults following the administration of a fixed mg/kg dose. 12 In a report from the Seattle group, BU Css o600 ng/mL was associated with graft rejection in 31 children receiving BU, CY and ATG for allogeneic grafts from various sources (25 HLA-matched siblings; 4 HLA-matched unrelated donors; 1 matched parent; 1 mismatched parent). 7 In addition, the same group reported that adjusting the BU dose to achieve a Css of 600-900 ng/mL increased the rate of engraftment from 74 to 96% in 24 children. 13 BU PK in children had been known to be age-dependent and variable, especially with oral dosing. In 2004, Nguyen et al.
14 demonstrated in a retrospective population PK analysis that i.v. BU doses in mg/kg adjusted to discrete weight categories achieved better AUC targeting. Weight-based dosing of i.v. BU was subsequently confirmed in a prospective study by Michel et al. 15 targeting AUC from 900 to 1500 mmol*min. Although the use of i.v. vs oral BU leads to lower variability in drug exposure, PK drug monitoring is still required if we are aiming for a narrow therapeutic window, in this case Css 600-700 ng/mL. 16, 17 In our series, 88% of the patients required BU dose adjustment to achieve a Css of 600-700 ng/mL despite i.v. administration. Values at the time of the last follow-up.
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In the initial multicenter transplant trial for children with SCD reported by Walters et al. 4 in 1996, BU was targeted to a Css of 400-600 ng/mL in only a few of the reported 22 patients. In that report, two patients died; one from GVHD and one of intracranial hemorrhage. The study did not report the incidence of SOS or stomatitis. The EFS and OS were 73% and 91%, respectively. A more recent French study reported on the outcome of 87 patients. 5 In that study, based on the results of BU PK, BU dosing in some patients was increased to 485 mg/m 2 , but never less than 16 mg/kg total dose. A total of six patients died of sepsis (n ¼ 1), cerebral hemorrhage (n ¼ 1) and GVHD (n ¼ 4). In addition, six patients experienced rejection. The EFS and OS were 86% and 93%, respectively. The Belgium group reported on 50 patients who received allogeneic SCT for SCD. 3 The conditioning regimen was BU based in all patients with no BU PKs measurements. In this study, EFS and OS were 85% and 93%, respectively. There were five (10%) patients who experienced graft rejection and two (4%) patients who died of transplant-related complications. McPherson et al. 18 reported on the effect of BU PK on the outcome of 25 patients with SCD receiving allogeneic BMT in a single center. In that study, the target BU level changed over time. The target BU Css was 400-600 ng/mL for five patients, o1000 ng/mL (with no lower limit) in 10 patients and 600-750 ng/mL for 10 patients. The authors reported that patients with sustained partial donor engraftment had a significantly lower BU AUC of 780-932 mmol* min (Css equivalent 533-637 ng/mL) compared to those with full donor engraftment 885-1305 mmol*min (Css equivalent 600-892 ng/ml). The authors observed eight cases (32%) of SOS, but interestingly, there was no correlation between the BU level and the development of SOS. In contrast to the report by McPherson et al., all our patients' BU were consistently targeted to Css 600-700 ng/mL (AUC equivalent 880-1020 mmol*min). We did not observe any cases of SOS, and none of the patients experienced graft rejection or death.
In the Belgian series, thirty-six patients had significant SCDrelated morbidity, whereas 14 patients had no pre-transplant morbidity and less than three prior transfusions. These 14 patients with minimal prior sickle cell-related complications had significantly fewer transplant-related events compared with the group of patients with severe disease. Most of our patients received transplants for SCD without significant prior morbidities. Eleven of our 16 patients were 6 years or younger. Mild pre-transplant SCD status and younger age could explain in part our excellent results.
Infertility is a barrier for some physicians to recommend transplant for SCD. Most of our patients are too young to evaluate gonadal function. In the five patients in whom measurement of gonadotropin levels was meaningful, two had evidence of gonadal dysfunction. This is within the expectation for recipients of a myeloablative alkylating agent-based preparative regimen. Long-term follow-up of patients in the Multicenter Investigation of bone marrow transplant for sickle cell disease using BU and CY regimens showed that the majority of patients experienced gonadal failure. Among evaluable male patients, four out of 13 patients tested had abnormal luteinizing hormone and folliclestimulating hormone levels and 10 out of 13 had abnormal testosterone levels; whereas eight of 14 females tested had either abnormal luteinizing hormone, follicle-stimulating hormone or estradiol levels and 75% had amenorrhea. 19 As gonadal toxicity may be correlated with the pubertal stage at the time of transplant, long-term follow-up of our young patients will be necessary to assess the ultimate gonadal function post transplant. Of interest, infertility was not a major concern for the eligible families we encountered.
We conclude that therapeutic BU dosing to Css of 600-700 ng/ mL in combination with CY and ATG can result in sustained donor engraftment and excellent OS in patients with SCD.
